{"id":4455,"date":"2026-10-07T08:15:43","date_gmt":"2026-10-07T02:45:43","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-07\/"},"modified":"2026-10-07T17:28:01","modified_gmt":"2026-10-07T11:58:01","slug":"glenmark-share-price-today-2026-10-07","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-07\/","title":{"rendered":"Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 1.24% | 7 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: GLENMARK<\/strong> \u00b7 7 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,282.30<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-1.24%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,325.30 \/ \u20b92,274.40<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,311.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>4.98 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>7 October 2026 \u00b7 03:15 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Glenmark Pharmaceuticals shares declined 1.24% today, settling at \u20b92,282.30 after touching an intraday high of \u20b92,325.30 and a low of \u20b92,274.40 from a previous close of \u20b92,311.00.<\/li>\n<li>Glenmark Therapeutics Inc., USA announced the commercial launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, 0.1%, a market that achieved annual sales of approximately $45.8 million according to Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new packaging enhances consumer convenience and strengthens its U.S. dermatology portfolio.<\/li>\n<li>Trading volume was 0.91 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Glenmark Pharmaceuticals share price falling on 7 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals shares declined 1.24% today, settling at \u20b92,282.30 after touching an intraday high of \u20b92,325.30 and a low of \u20b92,274.40 from a previous close of \u20b92,311.00.<\/p>\n<p class=\"wt-copy\">The broader market experienced downward pressure during the session, with the Nifty falling 0.76% and the Nifty Pharma sector benchmark retreating by 0.43%. Glenmark&#x27;s decline of 1.24% slightly underperformed the broader healthcare sector and benchmark indices, extending a short-term pullback that includes a 2.24% loss over the past 5 trading days and a 6.27% drop across the past 20 trading days.<\/p>\n<p class=\"wt-copy\">The price movement coincides with ongoing developments following the company&#x27;s recent operational updates, including the October 06, 2026 launch of Adapalene Gel USP, 0.1% (OTC) in pump packs in the United States and the September 23, 2026 receipt of a U.S. FDA Establishment Inspection Report with VAI classification for its Goa facility. While these recent disclosures provide fundamental context regarding its product pipeline and regulatory progress, no single direct catalyst was announced today to explicitly drive the session&#x27;s retracement.<\/p>\n<p class=\"wt-copy\">4.98 lakh shares traded by 7 October 2026 \u00b7 03:15 PM IST. This compares with a 20-day average daily volume of 5.44 lakh shares (0.91 times). The five-day average daily volume was 6.44 lakh shares. Separately, the NSE report for 6 October 2026 showed 2.77 lakh shares delivered, representing 56.11% of that day\u2019s traded volume. The same report recorded 40,035 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>profit-taking and sector-wide consolidation following recent multi-day weakness<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s 1.24% decline appears consistent with broader negative sentiment across headline indices and the pharma sector, combined with existing short-term retracement trends. No specific company-level event occurred today to prompt the move.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">US Launch of Adapalene Gel Pump Packs<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Glenmark Therapeutics Inc., USA announced the commercial launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, 0.1%, a market that achieved annual sales of approximately $45.8 million according to Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new packaging enhances consumer convenience and strengthens its U.S. dermatology portfolio.<\/p>\n<p class=\"wt-copy\">Expands Glenmark&#x27;s over-the-counter dermatology product offerings in the United States, targeting a well-established product category.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">U.S. FDA Inspection Report for Goa Facility<\/div>\n<div class=\"wt-card-date\">23 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals announced the receipt of the Establishment Inspection Report from the U.S. Food and Drug Administration for its formulations manufacturing facility in Goa, India. The inspection, conducted from June 22 to June 30, 2026, successfully closed with a Voluntary Action Indicated status. This classification indicates satisfactory resolution and compliance standards at the manufacturing site.<\/p>\n<p class=\"wt-copy\">Clears regulatory scrutiny for a key manufacturing facility, supporting export visibility and compliance confidence for regulated markets.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_23092026083959_SEPressRelease23092026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Ryaltris Nasal Spray Launch in Brazil<\/div>\n<div class=\"wt-card-date\">11 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Glenmark Specialty S.A. launched RYALTRIS Nasal Spray in Brazil for treating moderate to severe symptoms of allergic rhinitis in adults and adolescents aged 12 and older. The rollout follows regulatory approval from ANVISA and introduces the first olopatadine-containing intranasal combination therapy in Brazil. Allergic rhinitis affects an estimated 20-30% of the Brazilian population.<\/p>\n<p class=\"wt-copy\">Broadens the global footprint of Glenmark&#x27;s flagship innovative respiratory brand in Latin America&#x27;s largest healthcare market.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 06, 2026, titled &quot;Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 06, 2026, titled &quot;Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">46.65%<\/div>\n<div class=\"wt-note\">46.65% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">20.89%<\/div>\n<div class=\"wt-note\">20.34% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">39.49%<\/div>\n<div class=\"wt-note\">39.63% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1693887_16072026123852_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.76% on 30 June 2026. This compares with 16.80% on 31 March 2026, a change of -0.04 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 37 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND &#8211; HDFC MID-CAP FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">1.76 crore shares \u00b7 6.22%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">INVESCO INDIA CONTRA FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">62.18 lakh shares \u00b7 2.20%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">36.03 lakh shares \u00b7 1.28%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1693887_16072026123852_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b92,570.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Recommended as a stock pick by analyst Chandan Taparia, reflecting favorable technical positioning and growth outlook.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI Securities<\/div>\n<div class=\"wt-card-date\">4 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Hold<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b92,100.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a hold rating with a price target of Rs 2100 based on valuation and near-term business trajectory.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Sustained delivery percentage trends above 50% to gauge institutional and delivery-based accumulation<\/li>\n<li>Execution progress and revenue contribution from the recently launched Adapalene Gel pump packs in the U.S.<\/li>\n<li>Commercial ramp-up and market uptake of Ryaltris following its recent launch in Brazil<\/li>\n<li>Further updates regarding USFDA compliance status across other manufacturing facilities<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-06\/\">Why Glenmark Pharmaceuticals Shares Are Up 0.70% Today | 6 October 2026 \u2014 6 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-05\/\">Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026 \u2014 5 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-09-30\/\">Why Glenmark Shares Fell 4.37% Today: Sector Headwinds &amp; Volume Analysis | 30 September 2026 \u2014 30 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/glenmark\/\">More Glenmark Pharmaceuticals news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Glenmark Pharmaceuticals company news?<\/h3>\n<p class=\"wt-copy\">Glenmark Therapeutics Inc., USA announced the commercial launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, 0.1%, a market that achieved annual sales of approximately $45.8 million according to Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new packaging enhances consumer convenience and strengthens its U.S. dermatology portfolio.<\/p>\n<h3>How strong was Glenmark Pharmaceuticals\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">4.98 lakh shares traded, 0.91 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 \u00b7 03:15 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-07\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-07\/\"}, \"headline\": \"Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 1.24% | 7 October 2026\", \"description\": \"Glenmark Pharmaceuticals share price fell 1.24% to \u20b92,282.30 today. See why GLENMARK is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-07T02:45:43Z\", \"dateModified\": \"2026-10-07T17:27:50.936923+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/glenmark-company-news-2026-10-07.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 06, 2026, titled \\\"Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)\\\".\",\"source\":\"NSE\",\"published\":\"06-Oct-2026 08:38:46\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\",\"disclosure_text\":\"Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B\/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com October 6, 2026 To, National Stock Exchange of India Limited, \u201cExchange Plaza\u201d, 5th Floor, Plot No. C\/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai \u2013 400 051 To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 59\/26-27 Our Reference No. 59\/26-27 Dear Sir\/ Madam, Sub: Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC) Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch 1 of Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark\u2019s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin\u00ae2 Gel, 0.1%. According to Nielsen\u00ae syndicated data for the latest 52-week period ending September 5, 2026, the Differin\u00ae Gel, 0.1% (OTC) market3 achieved annual sales of approximately $45.8 million*. Kindly find attached media release which is self- explanatory. Request you to take the same on record. Thanking you. For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS \u2013 28839 Encl: As above Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC) Elmwood Park, New Jersey, October 06, 2026 \u2013 Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Adapalene Gel USP, 0.1% (OTC) in new pump packs . Glenmark\u2019s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin\u00ae2 Gel, 0.1%. According to Nielsen\u00ae syndicated data for the latest 52-week period ending September 5, 2026, the Differin\u00ae Gel, 0.1% (OTC) market3 achieved annual sales of approximately $45.8 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, \u201cThe introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio . This launch reflects our commitment to delivering high- quality and affordable healthcare solutions that meet evolving consumer needs.\u201d For product information and how to purchase, please visit: Adapalene Gel USP, 0.1% - 15 g Pump on Amazon Adapalene Gel USP, 0.1% - 45 g Pump on Amazon Adapalene Gel USP, 0.1% - 15 g Pump on Walmart.com Adapalene Gel USP, 0.1% - 45 g Pump on Walmart.com 1Glenmark\u2019s Adapalene Gel USP, 0.1% (OTC) is only marketed for the indications listed in Glenmark\u2019s approved drug facts label. 2This product is not manufactured or distributed by Galderma Laboratories, L.P. and\/or Galderma Holding S.A., distributor of DIFFERIN\u00ae Gel and owner of the registered trademark DIFFERIN\u00ae, respectively. [Galderma does not make or license Glenmark\u2019s product.] 3Market includes brand and all available therapeutic equivalents. Note: IQVIA\u00ae data obtained by Glenmark is only available for all approved RLD indications. Glenmark\u2019s product is only approved for and will only be marketed for the indications listed in Glenmark\u2019s approved label, which may be different than the approved RLD indications. *Nielsen\u00ae NIQ Discover; Syndicated Data for Period Ending September 5, 2026 About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research\u2010led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact: India United States Akhila Natarajan mediarelations@glenmarkpharma.com +91 22 4018 9999 Adfactors PR glenmark.ihcp@adfactorspr.com +91 9535635461 Akhila Natarajan mediarelations@glenmarkpharma.com Danielle Hagen danielle@nahigianstrategies.com 202-365-6112\"},{\"summary\":\"a press release dated October 06, 2026, titled \\\"Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 08:38:46\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 23, 2026, titled \\\"Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification\\\".\",\"category\":\"Press Release\",\"date\":\"23-Sep-2026 08:41:06\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_23092026083959_SEPressRelease23092026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 11, 2026, titled \\\"Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS\u00ae Launch in Brazil \\\".\",\"category\":\"Press Release\",\"date\":\"11-Sep-2026 08:50:55\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_11092026085036_Press_Release_11092026_Signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated August 21, 2026, titled \\\"Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg\/10 mL (100 mg\/mL), 5,000 mg\/50 mL (100 mg\/mL) Single-Dose Vials and 10,000 mg\/100 mL (100 mg\/mL) Pharmacy Bulk Package\\\".\",\"category\":\"Press Release\",\"date\":\"21-Aug-2026 08:52:14\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_21082026084736_Press_Release_21082026_Signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated October 06, 2026, titled \\\"Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 08:38:46\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 23, 2026, titled \\\"Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification\\\".\",\"category\":\"Press Release\",\"date\":\"23-Sep-2026 08:41:06\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_23092026083959_SEPressRelease23092026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 11, 2026, titled \\\"Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS\u00ae Launch in Brazil \\\".\",\"category\":\"Press Release\",\"date\":\"11-Sep-2026 08:50:55\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_11092026085036_Press_Release_11092026_Signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated August 21, 2026, titled \\\"Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg\/10 mL (100 mg\/mL), 5,000 mg\/50 mL (100 mg\/mL) Single-Dose Vials and 10,000 mg\/100 mL (100 mg\/mL) Pharmacy Bulk Package\\\".\",\"category\":\"Press Release\",\"date\":\"21-Aug-2026 08:52:14\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_21082026084736_Press_Release_21082026_Signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":46.65,\"public_pct\":53.35,\"fii_pct\":20.89,\"dii_pct\":18.6,\"mf_pct\":16.76,\"institutional_pct\":39.49,\"noninst_pct\":13.81,\"mf_scheme_count\":37,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC MUTUAL FUND - HDFC MID-CAP FUND\",\"shares\":17566947,\"pct\":6.22},{\"name\":\"INVESCO INDIA CONTRA FUND\",\"shares\":6217592,\"pct\":2.2},{\"name\":\"BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND\",\"shares\":3602621,\"pct\":1.28},{\"name\":\"UTI MULTI CAP FUND\",\"shares\":3258742,\"pct\":1.15}],\"period\":\"30-JUN-2026\",\"submission_date\":\"16-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1693887_16072026123852_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":46.65,\"previous_fii_pct\":20.34,\"previous_dii_pct\":19.29,\"previous_mf_pct\":16.8,\"previous_institutional_pct\":39.63,\"previous_mf_scheme_count\":36,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Buy\",\"target\":\"2570\",\"view_summary\":\"Stocks To Buy Today: Coforge, Timex To Glenmark Pharma \u2014 Five Stock Picks By Motilal Oswal's Chandan Taparia NDTV Profit\",\"headline\":\"Stocks To Buy Today: Coforge, Timex To Glenmark Pharma \u2014 Five Stock Picks By Motilal Oswal's Chandan Taparia\",\"published\":\"2026-08-31T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"ICICI Securities\",\"rating\":\"Hold\",\"target\":\"2100\",\"view_summary\":\"Hold Glenmark Pharmaceuticals; target of Rs 2100: ICICI Securities Moneycontrol.com\",\"headline\":\"Hold Glenmark Pharmaceuticals; target of Rs 2100: ICICI Securities\",\"published\":\"2026-08-04T07:00:00+00:00\",\"source\":\"Moneycontrol.com\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals share price fell 1.24% to \u20b92,282.30 today. See why GLENMARK is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":4454,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 1.24% | 7 October 2026","_witty_meta_description":"Glenmark Pharmaceuticals share price fell 1.24% to \u20b92,282.30 today. See why GLENMARK is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Glenmark Pharmaceuticals share price today","_witty_reason_label":"profit-taking and sector-wide consolidation following recent multi-day weakness","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[37],"class_list":["post-4455","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-glenmark"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=4455"}],"version-history":[{"count":6,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4455\/revisions"}],"predecessor-version":[{"id":5218,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4455\/revisions\/5218"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/4454"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=4455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=4455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=4455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}